May 4 (Reuters) - U.S. Food and Drug Administration:
* FDA APPROVES NEW USES FOR TWO DRUGS ADMINISTERED TOGETHER FOR THE TREATMENT OF BRAF-POSITIVE ANAPLASTIC THYROID CANCER
* FDA - APPROVES NEW USES FOR TWO DRUGS ADMINISTERED TOGETHER FOR TREATMENT OF BRAF-POSITIVE ANAPLASTIC THYROID CANCER
* FDA - APPROVED TAFINLAR, MEKINIST FOR TREATMENT OF ANAPLASTIC THYROID CANCER THAT CANNOT BE REMOVED BY SURGERY OR HAS SPREAD TO OTHER PARTS OF BODY Source text for Eikon: Further company coverage:
